Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie
Episode
42 min
Read time
2 min
Topics
Relationships, Startups, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓CAR-T Manufacturing Benchmarks: Kite's in-house manufacturing delivers product in 15–17 days with 96% first-run reliability, compared to competitor turnaround times of 30–40 days and roughly 80% reliability. Companies evaluating cell therapy partnerships should treat manufacturing speed and reliability as primary patient outcome variables, not secondary operational metrics.
- ✓Community Access Expansion: Kite grows its U.S. authorized treatment center network by 20–25 sites annually, now approaching 180 U.S. locations from over 570 globally. Securing FACT accreditation for community practices, released at ASH, is the regulatory mechanism unlocking outpatient delivery — a prerequisite before broader geographic access becomes feasible for next-generation therapies.
- ✓Collaboration Structure with Arcellx: Under the Anito-cel partnership, Arcellx contributes the therapeutic construct while Kite handles global manufacturing, regulatory affairs, and ex-U.S. commercialization. Both companies co-promote in the U.S. This division — innovation from the smaller partner, scale infrastructure from the larger — is presented as a replicable model for cell therapy commercialization broadly.
- ✓In Vivo Cell Therapy Bet-Hedging: Kite is pursuing both integrating and non-integrating in vivo approaches simultaneously following the Interius Biotherapeutics acquisition, which brought modular vector manufacturing and strong IP. A parallel strategic collaboration with China-based Pregene enables rapid construct iteration and faster phase-one entry under China's more flexible regulatory environment for regenerative therapies.
- ✓Research-to-Manufacturing Lock-Down Tension: The critical scaling decision in cell therapy is determining when to freeze a construct's design for manufacturing scale-up versus continuing research iteration. Kite manages this through structured tension between process development and research teams. Companies should establish explicit lock-down criteria before entering late-stage development to avoid manufacturing delays driven by incremental construct modifications.
What It Covers
Kite Pharma EVP Cindy Perettie details the operational, manufacturing, and commercial strategy behind scaling CAR-T cell therapies globally, covering the upcoming Anito-cel multiple myeloma launch, the Arcellx collaboration structure, next-generation pipeline development, and how Kite's manufacturing benchmarks outperform competitors across turnaround time and reliability metrics.
Key Questions Answered
- •CAR-T Manufacturing Benchmarks: Kite's in-house manufacturing delivers product in 15–17 days with 96% first-run reliability, compared to competitor turnaround times of 30–40 days and roughly 80% reliability. Companies evaluating cell therapy partnerships should treat manufacturing speed and reliability as primary patient outcome variables, not secondary operational metrics.
- •Community Access Expansion: Kite grows its U.S. authorized treatment center network by 20–25 sites annually, now approaching 180 U.S. locations from over 570 globally. Securing FACT accreditation for community practices, released at ASH, is the regulatory mechanism unlocking outpatient delivery — a prerequisite before broader geographic access becomes feasible for next-generation therapies.
- •Collaboration Structure with Arcellx: Under the Anito-cel partnership, Arcellx contributes the therapeutic construct while Kite handles global manufacturing, regulatory affairs, and ex-U.S. commercialization. Both companies co-promote in the U.S. This division — innovation from the smaller partner, scale infrastructure from the larger — is presented as a replicable model for cell therapy commercialization broadly.
- •In Vivo Cell Therapy Bet-Hedging: Kite is pursuing both integrating and non-integrating in vivo approaches simultaneously following the Interius Biotherapeutics acquisition, which brought modular vector manufacturing and strong IP. A parallel strategic collaboration with China-based Pregene enables rapid construct iteration and faster phase-one entry under China's more flexible regulatory environment for regenerative therapies.
- •Research-to-Manufacturing Lock-Down Tension: The critical scaling decision in cell therapy is determining when to freeze a construct's design for manufacturing scale-up versus continuing research iteration. Kite manages this through structured tension between process development and research teams. Companies should establish explicit lock-down criteria before entering late-stage development to avoid manufacturing delays driven by incremental construct modifications.
Notable Moment
Perettie describes how her first weeks inside a phase-one clinic at Sarah Cannon — watching cancer patients sit through 12-to-24-hour blood draw sessions — permanently changed her approach to clinical trial design, revealing that industry assumptions about patient-friendly protocols often do not reflect the actual burden on patients and caregivers.
Episode Transcript
Welcome back to the business of biotech. I'm your host, Ben Comer, chief editor at Life Science Leader. And today I'm speaking with Cindy Peretti, executive vice president and global head at Kite Pharma, a Gilead company focused on developing and commercializing curative CAR T cell therapies for cancer patients. Cindy is an experienced leader with the background including cancer research and life science industry leadership positions at Genentech, Roche, and Foundation Medicine. I'm excited to speak with Cindy about developing, scaling, and commercializing curative cell therapies at KITE, her approach to partnerships and collaborations, what she's learned from previous industry experiences, and what the future holds for cell therapy funding and product development. Thank you so much for being here, Cindy. Thank you, Ben. I'm really excited to be here. Yeah. I'm really glad to speak with you, as well. I think KITE's a really fascinating, organization and company. But I wanna start out with a little bit on your background, Cindy. You began your career, I think, as a research research associate at Johns Hopkins, and then as I mentioned in the intro, I went on to work for some of the biggest names in biotech, Genentech, and then Roche, where you worked as head of global oncology strategy, and then later as head of Roche Molecular Lab Solutions. You were also CEO at Foundation Medicine. What can you tell me, Cindy, about your initial decision, I guess to go from from the research field, into the life sciences industry? You know, it's interesting. When you're when you're working in basic research at an academic institution, it's really exciting. You're making discoveries, but what you realize is if you want to turn those discoveries into something that's going to scale for patients, then it makes a lot of sense to join industry because industry has the ability to do all of those things, to take amazing basic research and make it scale. And it'll you know, for me, it was about how you can have a broader impact. So it was it was a it was a good decision overall. What drew you to, to oncology in particular? You know, early early in life. I lost my grandfather to cancer and when I started doing research, there was a lot of interesting was at a time where, new genes were being found as it related to cancer and so your ability to do targeted treatments versus sort general chemotherapy was just coming to the forefront. And, so it was an exciting time, and I think that's what drew me from the professional side. Yeah. That that makes a lot of sense. I I'm also curious if that initial research experience that you had and then also your time I didn't mention this in the intro, but also the time you spent at at Sarah Cannon Research Institute, do you think that helped you, as a a biotech leader? And if so, how so? Yeah. It's interesting. So we …
Get the full transcript (7,789 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 39-minute episode.
Get Business Of Biotech summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Business Of Biotech
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
Sep 7 · 55 min
The Prof G Pod
China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge
Sep 8
More from Business Of Biotech
Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
Aug 31 · 58 min
Eye on AI
From 10 Drones a Month to Nearly 100,000 — Inside Ukraine's Largest Drone Manufacturer | Marko Kushnir, General Cherry
Sep 3
More from Business Of Biotech
We summarize every new episode. Want them in your inbox?
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil
Getting To A First Product Approval With Celcuity's Brian Sullivan
Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
Similar Episodes
Related episodes from other podcasts
The Prof G Pod
Sep 8
China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge
Eye on AI
Sep 3
From 10 Drones a Month to Nearly 100,000 — Inside Ukraine's Largest Drone Manufacturer | Marko Kushnir, General Cherry
Beyond Biotech
Aug 14
How Cancer Research Horizons is building the future of childhood cancer medicines
Beyond Biotech
Aug 7
Why Western pharma is sleeping on China's circular RNA revolution
The Knowledge Project
Jul 21
Truth Over Feelings: Inside Opendoor’s Massive Turnaround
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Startups & Product Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Business Of Biotech.
Every Monday, we deliver AI summaries of the latest episodes from Business Of Biotech and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime